The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice

Antonio Salar; Corinne Haioun; Francesca G. Rossi; Ulrich Duehrsen; Ruth Pettengell; Hans E. Johnsen; Ulrich Jaeger; Gregor Verhoef; Matthias Schwenkglenks; Pamela Bacon; Kate Bendall; Pieternella J. Lugtenburg

doi:10.1016/j.leukres.2012.02.002

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice

Antonio Salar, Corinne Haioun, Francesca G. Rossi, Ulrich Duehrsen, Ruth Pettengell, Hans E. Johnsen, Ulrich Jaeger, Gregor Verhoef, Matthias Schwenkglenks, Pamela Bacon, Kate Bendall, Pieternella J. Lugtenburg

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.

Original language	English
Pages (from-to)	548-553
Number of pages	6
Journal	Leukemia Research
Volume	36
Issue number	5
DOIs	https://doi.org/10.1016/j.leukres.2012.02.002
Publication status	Published - May 2012

Keywords

Diffuse large B-cell lymphoma
Febrile neutropenia
Granulocyte colony stimulating factor
R-CHOP-21
Relative dose intensity
Risk assessment

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.leukres.2012.02.002

Cite this

Salar, A., Haioun, C., Rossi, F. G., Duehrsen, U., Pettengell, R., Johnsen, H. E., Jaeger, U., Verhoef, G., Schwenkglenks, M., Bacon, P., Bendall, K., & Lugtenburg, P. J. (2012). The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice. Leukemia Research, 36(5), 548-553. https://doi.org/10.1016/j.leukres.2012.02.002

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21 : Findings from clinical practice. / Salar, Antonio; Haioun, Corinne; Rossi, Francesca G.; Duehrsen, Ulrich; Pettengell, Ruth; Johnsen, Hans E.; Jaeger, Ulrich; Verhoef, Gregor; Schwenkglenks, Matthias; Bacon, Pamela; Bendall, Kate; Lugtenburg, Pieternella J.

In: Leukemia Research, Vol. 36, No. 5, 05.2012, p. 548-553.

Research output: Contribution to journal › Article › peer-review

Salar, A, Haioun, C, Rossi, FG, Duehrsen, U, Pettengell, R, Johnsen, HE, Jaeger, U, Verhoef, G, Schwenkglenks, M, Bacon, P, Bendall, K & Lugtenburg, PJ 2012, 'The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice', Leukemia Research, vol. 36, no. 5, pp. 548-553. https://doi.org/10.1016/j.leukres.2012.02.002

Salar, Antonio ; Haioun, Corinne ; Rossi, Francesca G. ; Duehrsen, Ulrich ; Pettengell, Ruth ; Johnsen, Hans E. ; Jaeger, Ulrich ; Verhoef, Gregor ; Schwenkglenks, Matthias ; Bacon, Pamela ; Bendall, Kate ; Lugtenburg, Pieternella J. / The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21 : Findings from clinical practice. In: Leukemia Research. 2012 ; Vol. 36, No. 5. pp. 548-553.

@article{e3adbc1fb3384cbdb09cef99ba1f23bf,

title = "The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice",

abstract = "Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.",

keywords = "Diffuse large B-cell lymphoma, Febrile neutropenia, Granulocyte colony stimulating factor, R-CHOP-21, Relative dose intensity, Risk assessment",

author = "Antonio Salar and Corinne Haioun and Rossi, {Francesca G.} and Ulrich Duehrsen and Ruth Pettengell and Johnsen, {Hans E.} and Ulrich Jaeger and Gregor Verhoef and Matthias Schwenkglenks and Pamela Bacon and Kate Bendall and Lugtenburg, {Pieternella J.}",

year = "2012",

month = may,

doi = "10.1016/j.leukres.2012.02.002",

language = "English",

volume = "36",

pages = "548--553",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21

T2 - Findings from clinical practice

AU - Salar, Antonio

AU - Haioun, Corinne

AU - Rossi, Francesca G.

AU - Duehrsen, Ulrich

AU - Pettengell, Ruth

AU - Johnsen, Hans E.

AU - Jaeger, Ulrich

AU - Verhoef, Gregor

AU - Schwenkglenks, Matthias

AU - Bacon, Pamela

AU - Bendall, Kate

AU - Lugtenburg, Pieternella J.

PY - 2012/5

Y1 - 2012/5

N2 - Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.

AB - Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.

KW - Diffuse large B-cell lymphoma

KW - Febrile neutropenia

KW - Granulocyte colony stimulating factor

KW - R-CHOP-21

KW - Relative dose intensity

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=84858748086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858748086&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.02.002

DO - 10.1016/j.leukres.2012.02.002

M3 - Article

C2 - 22385870

AN - SCOPUS:84858748086

VL - 36

SP - 548

EP - 553

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 5

ER -

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this